Zobrazeno 81 - 90
of 453
pro vyhledávání: '"Andrew J. Carroll"'
Autor:
Alice S. Mims, Jessica Kohlschmidt, Sophia E. Maharry, Jonathan E. Kolitz, Christopher J. Walker, Shelley Orwick, Eunice S. Wang, Bayard L. Powell, James S. Blachly, Ann-Kathrin Eisfeld, Richard Stone, John C. Byrd, Deedra Nicolet, Albert de la Chapelle, Krzysztof Mrózek, Andrew J. Carroll, Clara D. Bloomfield
Publikováno v:
Leukemia
Targeted mutation assessment of 81 genes in 1021 adults with de novo acute myeloid leukemia (AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 52 (5.1%) patients, including 36 (5.2%) younger and 16 (4.8%) older patients, which
Autor:
Sophia E. Maharry, Jonathan E. Kolitz, Jessica Kohlschmidt, Richard Stone, Eunice S. Wang, Bayard L. Powell, James S. Blachly, Clara D. Bloomfield, Christopher J. Walker, Krzysztof Mrózek, Ann-Kathrin Eisfeld, Andrew J. Carroll, Deedra Nicolet, John C. Byrd, Shelley Orwick, Albert de la Chapelle
Publikováno v:
Leukemia
Thus far, only 5-15% of AML patients aged ≥60 years are cured with chemotherapy. Identification of patients who are less (more) likely to respond to standard chemotherapy might enable early risk stratification toward alternative treatment regimens.
Autor:
Andrew J. Carroll, Mignon L. Loh, Naomi J. Winick, Cindy Wang, Eric Larsen, Nyla A. Heerema, Leonard A. Mattano, Kimberly P. Dunsmore, Brent L. Wood, Stuart S. Winter, Elizabeth A. Raetz, William L. Carroll, Patrick A. Brown, Si Chen, Stephen P. Hunger, Kelly W. Maloney, Sumit Gupta, Julie M. Gastier-Foster, Meenakshi Devidas, Michael J. Borowitz
Publikováno v:
Leukemia. 32:1370-1379
Minimal residual disease (MRD) after initial therapy is integral to risk stratification in B-precursor and T-precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although MRD determines depth of remission, remission remains defined by morphology. W
Autor:
Mignon L. Loh, Nyla A. Heerema, Eric Larsen, Naomi J. Winick, Heng Xu, Meenakshi Devidas, Elaine R. Mardis, Mary V. Relling, Takaya Moriyama, Elizabeth A. Raetz, Yunfeng Dai, Gerard P. Zambetti, Paul L. Martin, Ching-Hon Pui, Cheng Cheng, William E. Evans, Wenjian Yang, Kim E. Nichols, Brent L. Wood, W. Paul Bowman, Andrew J. Carroll, William L. Carroll, Julie M. Gastier-Foster, Xueyuan Cao, Maoxiang Qian, Stephen P. Hunger, Charles G. Mullighan, Robert S. Fulton, Michael J. Borowitz, Hui Zhang, Jun J. Yang
Publikováno v:
Journal of Clinical Oncology. 36:591-599
Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this t
Autor:
Karilyn Larkin, Deedra Nicolet, Ben Kelly, Krzysztof Mrózek, Katherine E Miller, Saranga Wijeratne, Stephanie LaHaye, Jessica Kohlschmidt, James S. Blachly, Alice S. Mims, Christopher J. Walker, Christopher C. Oakes, Shelley Orwick, Isaiah Boateng, Jill Buss, Adrienne Heyrosa, Andrew J Carroll, William Blum, Bayard L. Powell, Jonathan E Kolitz, Joseph O. Moore, Robert James Mayer, Richard A. Larson, Richard M. Stone, Electra D. Paskett, John C. Byrd, Elaine R. Mardis, Ann-Kathrin Eisfeld
Publikováno v:
Blood. 138:221-221
Background: AML is a highly aggressive hematologic malignancy. Patient (pt) outcomes are affected by disease-related factors including cytogenetic findings and gene mutations, as well as pt-related factors, such as age and race. Younger pts have supe
Autor:
Brian Giacopelli, Maria R. Baer, Ann-Kathrin Eisfeld, Kyoko Yamaguchi, Yue-Zhong Wu, James S. Blachly, Salma Abdelbaky, Clara D. Bloomfield, Christopher C. Oakes, Bayard L. Powell, Jessica Kohlschmidt, Kevin R. Coombes, John C. Byrd, Deedra Nicolet, Krzysztof Mrózek, Richard Stone, William Blum, Shelley Orwick, Andrew J. Carroll, Ada C Cleary, Jonathan E. Kolitz
Publikováno v:
Blood. 138:803-803
Genetic profiling of leukemic cells forms the basis for risk stratification in acute myeloid leukemia (AML). Genetic markers in AML are used to make recommendations for distinct treatment approaches, such as remission consolidation with chemotherapy
Autor:
Jessica Kohlschmidt, Richard Stone, Andrew J. Carroll, Jonathan E. Kolitz, James S. Blachly, Bayard L. Powell, John C. Byrd, Ann-Kathrin Eisfeld, Michael Ozga, Christopher J. Walker, Krzysztof Mrózek, Alice S. Mims, Richard A. Larson, Deedra Nicolet, Shelley Orwick
Publikováno v:
Blood. 138:3369-3369
Background: WBC levels vary widely in AML pts at diagnosis. Together with various cytogenetic and molecular abnormalities, WBC is a main prognostic factor for AML pts. Treatment decisions like need for intrathecal chemotherapy, trial enrollment eligi
Autor:
Natalie Delrocco, Mignon L. Loh, Michael Borowitz, Karen R Rabin, Patrick A Zweidler-McKay, Kelly W Maloney, Leonard A. Mattano, Eric C Larsen, Anne L Angiolillo, Reuven J Schore, Michael J. Burke, Wanda L Salzer, Brent L. Wood, Andrew J Carroll, Nyla A. Heerema, Shalini C Reshmi, Julie M Gastier-Foster, Richard C Harvey, I-Ming L Chen, Kathryn G Roberts, Charles G. Mullighan, Cheryl L Willman, Naomi J Winick, William L. Carroll, Stephen P. Hunger, Elizabeth A. Raetz, Meenakshi Devidas, John Kairalla
Publikováno v:
Blood. 138:2382-2382
Contemporary risk stratification algorithms commonly use threshold-defined categories of clinically relevant risk factors. The Children's Oncology Group (COG) uses National Cancer Institute (NCI) risk group (RG), cytogenetics, and early response to t
Autor:
Wolfgang Hiddemann, Christopher C. Oakes, Dennis Görlich, Aarif M. N. Batcha, Alice S. Mims, Shelley Orwick, Stephanie Schneider, Maria Cristina Sauerland, Christopher J. Walker, Karilyn Larkin, Richard Stone, Vindi Jurinovic, Maja Rothenberg-Thurley, Klaus H. Metzeler, Joseph O. Moore, William Blum, James S. Blachly, Andrew J. Carroll, Karsten Spiekermann, Bernhard J. Woermann, Utz Krug, John C. Byrd, Jessica Kohlschmidt, Jan Braess, Richard A. Larson, Deedra Nicolet, Robert J. Mayer, Wolfgang E. Berdel, Bayard L. Powell, Jonathan E. Kolitz, Ann-Kathrin Eisfeld, Monica Cusan, Krzysztof Mrózek, Tobias Herold
Publikováno v:
Blood. 138:685-685
Background: AML is a disease affecting predominantly older patients (pts), but does occur across the entire age spectrum; younger adults [age Methods: We analyzed the molecular profiles of 2,823 adult AML pts enrolled onto clinical frontline protocol
Autor:
Yazan F. Madanat, James S. Blachly, John C. Byrd, Prapti A. Patel, Christopher J. Walker, Ravi Patel, Richard D. Press, Kendra Sweet, Maria R. Baer, Fei Yang, Richard Stone, Michael Ozga, Akriti G Jain, Luke B Fletcher, Richard A. Larson, Deedra Nicolet, William Blum, Jonathan E. Kolitz, Jessica Kohlschmidt, Chetasi Talati, Alice S. Mims, Ann-Kathrin Eisfeld, Andrew J. Carroll, Uma Borate, Dan Jones, Bayard L. Powell, Guido Marcucci, Krzysztof Mrózek, Virginia O. Volpe
Publikováno v:
Blood. 138:226-226
Background : The identification of mutations in IDH1 and IDH2 in ~20% of AML pts has ushered in the modern era of precision medicine in AML. The functional implications of the resulting neomorphic activity of these mutated enzymes, has resulted in FD